IFNL4 rs12979860: What Your Genotype Means
The rs12979860 single nucleotide polymorphism is an intronic variant in the IFNL4 gene region on chromosome 19. Historically known for its strong statistical association with spontaneous hepatitis C virus clearance and response to pegylated interferon regimens, the variant reflects host immune variation. With the advent of direct-acting antiviral therapies, its modern clinical testing utility is substantially reduced.
What each genotype means
Favorable interferon response
This genotype is historically associated with a higher likelihood of achieving sustained virologic response when treated with peginterferon and ribavirin for hepatitis C. While modern direct-acting antiviral therapies have significantly improved cure rates for all genotypes, research suggests this variant may still influence viral clearance and treatment outcomes. Please discuss your specific clinical situation and treatment options with your healthcare provider.
This is the most common genotype in many populations, including approximately 70% of individuals of European ancestry and over 90% of those of East Asian ancestry.
Intermediate interferon response
Individuals with this genotype often show intermediate outcomes regarding hepatitis C viral clearance compared to those with the CC or TT genotypes. While this variant was a key predictor for older interferon-based therapies, its clinical relevance in the era of modern direct-acting antivirals is less pronounced. You should consult with your clinician or pharmacist to understand how your genetic profile might relate to your specific medical management.
This genotype is found at varying frequencies globally, appearing in a significant portion of individuals across diverse ancestral backgrounds.
Unfavorable interferon response
This genotype is associated with a lower probability of spontaneous hepatitis C clearance and historically lower response rates to peginterferon-based treatments. Although modern direct-acting antiviral regimens have largely superseded the need for interferon, some studies suggest this genotype may still be linked to slower viral decay or higher relapse risks in certain treatment contexts. Always discuss your treatment plan and any concerns regarding medication efficacy with your healthcare provider.
This genotype is less common in East Asian populations but is observed more frequently in individuals of African ancestry, where it may be present in a significant percentage of the population.
Genomic Location and the IFNL3/IFNL4 Region
The rs12979860 variant is a single nucleotide polymorphism located on chromosome 19. When first discovered through early genome-wide association studies, it was commonly designated as an IL28B (IFNL3) marker because of its physical proximity upstream of that gene. Subsequent molecular research demonstrated that the variant actually resides within the first intron of the neighboring IFNL4 gene. The polymorphism consists of an exchange between a cytosine (C) and a thymine (T) allele. Because the locus features significant genomic complexity, rs12979860 often acts as a surrogate marker that exists in strong linkage disequilibrium with other nearby functional variants in the IFNL4 cluster, including the frameshift polymorphism rs11322783 (also known as ΔG/TT). This genomic architecture makes rs12979860 one of the most widely characterized historical markers for antiviral pharmacogenomics.
Biological Role and the IFNL4 Paradox
The IFNL4 gene encodes interferon lambda 4, a member of the type III interferon family of cytokines involved in innate antiviral defense. When type III interferons bind their receptors, they activate intracellular signaling cascades, notably the Jak-STAT pathway, driving the expression of interferon-stimulated genes. In human populations, researchers observed an intriguing immunological paradox: individuals who produce a fully functional IFNL4 protein often exhibit reduced spontaneous clearance of hepatitis C virus and experienced lower cure rates under older interferon-alpha regimens. Conversely, genetic variations that disable or reduce IFNL4 activity—such as alleles in tight linkage with the rs12979860 C allele—are associated with enhanced clearance. Chronic basal activation of interferon-stimulated genes in individuals expressing functional IFNL4 is hypothesized to cause a state of immune refractoriness, diminishing the host's ability to eliminate the virus.
Historical Association and Evidence Strength
The association between rs12979860 and hepatitis C outcomes is well-documented in hundreds of peer-reviewed clinical studies. The C allele, especially in the homozygous CC state, was historically considered a favorable pharmacogenomic marker, yielding substantially higher rates of sustained virologic response when patients were treated with combined pegylated-interferon-alfa and ribavirin. However, the variant's clinical strength is categorized as limited in modern practice. The development and widespread adoption of highly potent direct-acting antivirals (DAAs), such as sofosbuvir-based regimens, achieved cure rates exceeding 95% across virtually all patient subgroups regardless of host host genetics. While some observational studies have evaluated whether IFNL4 variants slightly influence treatment duration or residual fibrosis progression, DAA efficacy has largely superseded pre-treatment genetic testing for rs12979860 in standard hepatology guidelines.
Ancestral Diversity and Linkage Differences
Allele frequencies for rs12979860 demonstrate profound geographic and ancestral variation across global populations. The favorable C allele is observed at high frequencies in East Asian populations (approximately 90% to 95%) and is also common among individuals of European ancestry (around 70%). In contrast, the C allele is markedly less prevalent in populations of African ancestry, where frequencies typically range between 30% and 40%, making the T allele the majority allele. Furthermore, the degree of linkage disequilibrium between rs12979860 and the causative functional frameshift variant rs11322783 differs substantially by background. While rs12979860 is an excellent proxy for the underlying functional locus in European and Asian ancestries, the correlation is lower in African populations, meaning rs12979860 alone is less predictive of true IFNL4 protein status in individuals of African descent.
Understanding Your Results in Modern Healthcare
Discovering your rs12979860 genotype through personal genetic testing provides interesting historical and immunological context, but it does not represent a standalone medical diagnosis. A genotype cannot determine whether you have an active viral infection or predict overall liver health in isolation. Because modern hepatitis C therapies utilize targeted direct-acting antivirals that overcome host genetic barriers, knowing your rs12979860 genotype rarely changes first-line therapy choices. Readers should never attempt to adjust, initiate, or discontinue any medications based on personal genetic reports. For any concerns regarding liver function, viral hepatitis screening, or personalized pharmacology, always consult a qualified hepatologist, primary care clinician, or clinical pharmacist.
How common is this variant?
The C allele frequency is approximately 90% to 95% in East Asians and roughly 70% in Europeans, but drops to around 30% to 40% in individuals of African ancestry.
Frequently asked questions
Does my rs12979860 genotype mean I have hepatitis C?
No, your rs12979860 genotype does not diagnose hepatitis C or any other infection. It is an inherited germline marker that researchers studied to observe how different immune systems historically cleared the virus. Diagnosing hepatitis C requires specific clinical blood tests, such as HCV antibody and viral RNA assays.
Is genetic testing for rs12979860 still required before hepatitis C treatment?
In current clinical practice, testing for rs12979860 is no longer routinely recommended. Modern direct-acting antivirals achieve cure rates above 95% across virtually all host genotypes, effectively superseding the need for older host pharmacogenomic stratification.
Why is the variant sometimes labeled as IL28B instead of IFNL4?
When rs12979860 was first identified via genome-wide association studies, it was mapped closest to the IL28B gene (now known as IFNL3). Subsequent fine-mapping demonstrated that the variant is actually located within the first intron of the nearby IFNL4 gene.
Can I use my genotype to decide which antiviral medication to take?
No, you should never choose or alter any antiviral medication based solely on a direct-to-consumer genetic result. Prescription choices depend on viral genotype, liver staging, and medication interactions evaluated by your clinician or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12979860?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IFNL4
Variant in the IFNL4 region associated with spontaneous clearance of hepatitis C virus and response to interferon therapy.
Intronic variant near IFNL3/IFNL4 predicting spontaneous and treatment-induced clearance of Hepatitis C virus infection.